Form 4: Coherus BioSciences CEO Dennis Lanfear Acquires 375,000 Stock Options

Dennis M. Lanfear, President & CEO of Coherus BioSciences, Inc., was granted 375,000 stock options on May 7, 2025, according to a Form 4 filing with the SEC.

Summary

• According to a Form 4 filing with the SEC, Dennis M. Lanfear, the President & CEO of Coherus BioSciences, Inc., acquired 375,000 stock options on May 7, 2025.
• The options have an exercise price of $0.9462.
• The options vest over four years, with 1/4th vesting on May 7, 2026, and the remaining 1/48th vesting monthly thereafter, contingent upon continued service with Coherus BioSciences.
• The options expire on May 7, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options is a standard practice and suggests confidence in the company's future performance.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
• Companies like Amgen, Gilead, and Biogen also utilize stock options as part of their executive compensation strategy.
• The vesting schedule and exercise price are typical for such grants.

Stakeholder Impact

• The stock option grant aligns the CEO's interests with those of shareholders, potentially leading to increased shareholder value.

Key Dates

Keywords

Coherus BioSciences, Dennis Lanfear, Stock Options, Form 4, SEC Filing, Executive Compensation